Children & Adolescents
Children & Adolescents
Updated Guidelines for Antiretroviral Treatment of Children with HIV
- Details
- Category: HIV Treatment Guidelines
- Published on Friday, 14 February 2014 00:00
- Written by DHHS
The Department of Health and Human Services this week updated its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Changes to the children's guidelines include specific drug recommendations and information about a possible cure of an HIV-infected infant following very early treatment.
FDA Approves Oral Raltegravir for Children with HIV
- Details
- Category: Children & Adolescents
- Published on Friday, 10 January 2014 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last month approved a new dosage form of the HIV integrase inhibitor raltegravir (Isentress). The new raltegravir oral suspension is indicated for pediatric patients age 4 weeks or older weighing 3-20 kg (about 7-44 lb).
Early Time-limited Treatment Leads to Better Outcomes for Infants with HIV
- Details
- Category: Children & Adolescents
- Published on Wednesday, 28 August 2013 00:00
- Written by Liz Highleyman
Infants with HIV who start antiretroviral therapy (ART) immediately after birth had a lower risk of disease progression or death and were able to safely interrupt treatment longer than children who started ART later, according to findings from the long-running CHER study published in the August 22, 2013, advance online edition of The Lancet.
Updated Pediatric HIV Opportunistic Infection Guidelines Emphasize Antiretroviral Therapy
- Details
- Category: Opportunistic Illness (OIs)
- Published on Monday, 11 November 2013 00:00
- Written by AIDSinfo
The U.S. National Institutes of Health, Centers for Disease Control and Prevention, and other medical associations have released an updated version of Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. The latest revision emphasizes the importance of timely antiretroviral therapy as a key to preventing and managing OIs in infants and children with HIV.
IAS 2013: Lower-dose Lopinavir/Ritonavir Reduces Side Effects, Maintains Viral Control in HIV+ Children
- Details
- Category: Children & Adolescents
- Published on Wednesday, 14 August 2013 00:00
- Written by Carole Leach-Lemens
Low dose lopinavir/ritonavir (Kaletra or Aluvia) -- 70% of the standard dose -- worked as well as the standard dose in maintaining viral suppression, but with less dyslipidemia, among children with HIV in Thailand, Thanyawee Puthanakit reported on behalf of the HIVNAT 152 PEARL study at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
Web Design and Development by